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Abstract: Tumor hypoxia is associated with adverse outcome in many malignancies. The goal of this study was to determine 
if elevated expression of carbonic anhydrase IX (CAIX), a biomarker of hypoxia, predicts for recurrence in early-stage 
cervical cancer. The charts of all patients with early-stage cervical cancer, primarily FIGO IB, treated by radical hysterectomy 
at our institution from 1988–2001 were reviewed. Adequate pathologic specimens from patients who recurred or who had 
at least three years follow-up and remained disease-free were stained for CAIX. An immunohistochemical score (IHC) was 
generated from the extent/intensity of staining. Outcome, as measured by freedom from recurrence (FFR), distant metasta-
ses (FFDM) and local recurrence (FFLR), was analyzed as a function of age, IHC, lymph node status (LN) and histology. 
Forty-two relapsing patients and 76 non-relapsing patients were evaluated. In univariate analysis, +LN, though not IHC or 
histology, was a signiﬁ  cant predictor of any recurrence. Both +LN and higher IHC were associated with decreased FFDM 
but not FFLR. Patients with both +LN and elevated IHC more frequently exhibited distant metastases as ﬁ  rst site of failure 
(5-year FFDM 50%) than patients with only +LN, elevated IHC or neither feature (70, 85 and 95%, respectively, p = 0.0004). 
In multivariable analysis, only +LN was signiﬁ  cantly associated with poorer FFDM (hazard ratio 4.6, p = 0.0015) though 
there was a strong trend with elevated CAIX expression (p = 0.069). Elevated CAIX expression is associated with more 
frequent distant metastases in early-stage cervical cancer, suggesting that patients with this characteristic may beneﬁ  t from 
more aggressive treatment.
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Introduction
In a variety of human cancers, including soft tissue sarcomas, head-and-neck squamous cell carcinomas 
and cancer of the uterine cervix, tumor hypoxia is associated with an increased incidence of metastases, 
decreased progression-free survival and poor outcome (Dische et al. 1983; Fein et al. 1995; Höckel et al. 
1996 and 1999; Brizel et al. 1996 and 1997; Nordsmark et al. 1996; Wykoff et al. 2000; Vordermark and 
Brown, 2003; Kim et al. 2005). As a marker for unfavorable prognosis, hypoxia has been targeted in a 
variety of ways and is the subject of active ongoing clinical research. This includes a phase III trial for 
patients with cervical cancer receiving chemoradiation who are randomized to standard therapy with or 
without tirapazamine, a hypoxic cell sensitizer (GOG 0219). To date, clinical efforts have primarily 
focused on the role of hypoxia in locally advanced cancers. However, there are subsets of early-stage 
cancer patients who have unexpectedly poor clinical outcomes. This retrospective study focuses on a 
large group of patients with early-stage cervical cancer treated deﬁ  nitively with radical surgery.
Tumor hypoxia (PO2) has been shown to promote the selection of cells with reduced apoptotic 
potential (Graeber et al. 1996), to increase the frequency of mutations (Reynolds et al. 1996; Sutherland, 
1998), to induce genes promoting angiogenesis (Dachs and Chaplin, 1998) and to decrease radiosen-
sitivity (Gray et al. 1953; Bedford and Mitchell, 1974). Endogenous hypoxia biomarkers are genes or 
gene products speciﬁ  cally up-regulated under hypoxic conditions. Candidate biomarkers have included 
hypoxia-inducible factor 1-α (HIF-1α) and its downstream products, vascular endothelial growth actor 
(VEGF) and metallomatrixproteinases (Kim et al. 2005; Moon et al. 2007; Harris, 2002). Carbonic 
anhydrase 9 (CA9, Opavsky et al. 1996) is a HIF-1 target gene (Wykoff et al. 2000) whose product, 46
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carbonic anhydrase IX (CAIX), has been investi-
gated as an endogenous hypoxia biomarker (Olive 
et al. 2001). CAIX is a transmembrane protein that 
catalyzes the reversible hydration of carbon diox-
ide to carbonic acid, regulating intracellular pH 
(Ivanov et al. 1998). Thus, CAIX appears to help 
maintain a normal pH in tumor cells under hypoxic 
conditions, allowing tumors to acclimate to a hos-
tile microenvironment. In turn, this facilitates 
tumor proliferation in hypoxic regions (Blancher 
and Harris, 1998; Yamagata et al. 1998).
We hypothesized that tumor hypoxia might be 
associated with an inherently more malignant 
phenotype expressed at a relatively early point in 
the evolution of these tumors. This retrospective 
study explores the association between CAIX 
expression, other tumor/patient factors and out-
come in early-stage cervical cancer (primarily 
FIGO IB) treated deﬁ  nitively by radical hysterec-
tomy.
Materials and Methods
Patients
This was a single-institution retrospective study, 
approved by the Institutional Review Board. We 
reviewed the charts of all women who underwent 
a radical hysterectomy (RH) at Duke University 
Medical Center as deﬁ  nitive treatment for early-
stage cervical cancer between 1988 and 2001. A 
total of 315 patients, predominantly FIGO stage 
IB, were identiﬁ  ed. Pathologic specimens from any 
patient who either recurred (96 patients) or who 
had a follow-up of at least three years and remained 
disease-free (49 patients) were examined by a 
pathologist blinded to outcome (RCB). In turn, 
those blocks with adequate tumor specimens (118 
total patients) were cut and the slides stained for 
carbonic anhydrase IX (CAIX).
CAIX staining
Immunohistochemistry was performed using 5-μm 
sections of formalin-fixed, paraffin-embedded 
tissues placed onto positively charged glass slides, 
followed by routine dewaxing and rehydration. 
Negative controls were included by omission of 
the primary antibody. CAIX expression was 
detected using anti-CAIX mouse monoclonal 
antibody clone M75 (gift from E. Oosterwijk, 
University Hospital Nijmegen, Nijmegen, 
Netherlands). After peroxidase was quenched with 
methanol and 3% hydrogen peroxide for 10 
minutes, microwave antigen retrieval was done 
twice on 600W for 5 minutes each. After blocking 
with 10% donkey serum, the slides were incubated 
with the primary antibody (3 μg/ml) overnight at 
4 °C, and washed with Tris-buffered saline. 
Biotinylated donkey antimouse antibody (1:1000 
volume/volume, Jackson ImmunoResearch, West 
Grove, PA) was applied for 30 minutes at room 
temperature, followed by application of ABC kit 
(Vector Lab, Inc., Burlingame, CA, USA).
Following staining, specimens were evaluated 
by two other pathologists (ZNR, MEH) blinded to 
the patient identity and clinical outcome. On each 
slide, the entire area containing tumor was exam-
ined under low power (40X). Each pathologist 
determined intensity (0 = no staining, 1 = mild 
staining, 2 = moderate staining, 3 = strong staining) 
and the extent of all tumor cells (0%–100%) with 
each intensity of staining, independently. Repre-
sentative examples are shown in Figure 1. For the 
purposes of this analysis, only the product of the 
strong intensity (3) and the average extent of stain-
ing for this intensity was used to calculate the 
immunohistochemical (IHC) score for each spec-
imen. A breakpoint of  30% versus  30% IHC 
score was selected for the outcome analyses, as the 
outcome of the groups falling above versus below 
this value appeared quite different and there was 
an adequate number of patients for statistical 
analysis within each group.
Statistics
Survival curves were generated (Kaplan and Meier, 
1958) and compared by the log-rank test (Mantel 
and Haenszel, 1958). The associations of patient/
tumor characteristics with survival were deter-
mined by multivariable Cox proportional-hazards 
analyses (Cox, 1972). The principal endpoints 
examined were freedom from recurrence (FFR), 
freedom from distant metastases as the ﬁ  rst site of 
recurrence (FFDM) and freedom from local fail-
ures as the ﬁ  rst site of recurrence (FFLR). When 
recurrence was detected simultaneously at distant 
sites and locally, the patient was scored as having 
both a local recurrence and distant failure on that 
date. The multivariable proportional hazard model 
was built using forward stepwise selection. In 
building this model, the effect of the independent 
variables (age, lymph node status, IHC score and 47
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histology) were tested, as well as the cross products 
(e.g., lymph nodes status x IHC score) of these 
variables. All p-values reported were two-sided 
and statistical signiﬁ  cance was deﬁ  ned as p   0.05. 
Statistical analyses were performed using JMP 
software version 6 (SAS Institute, Inc., Cary, North 
Carolina).
Results
Forty-two relapsing patients and 76 non-relapsing 
patients with a minimum of 3 years follow-up had 
adequate pathology specimens and were included 
in the analysis (Table 1.) In the overall group of 
118 patients, the median follow-up was 59.6 
months (range 4–195 months), the median age at 
the time of surgery was 44.9 years (range 
19.4–79.8 years) and 27 patients were found to 
have positive pelvic and/or para-aortic lymph 
Negative = 0 Mild = 1
Severe = 3 Moderate = 2
Figure 1. Examples of CAIX staining intensity of human cervical cancer: a. none = 0, b. mild = 1, c. moderate = 2, d. strong = 3.
Table 1. Patient and tumor characteristics.
Patients with adequate pathology 
specimens
118
 Patients  with  recurrence 42
  Patients without recurrence 76
Median Follow-Up (months) 59.6
 Range 4–195
Median Age (years) 45
 Range 19–79
Positive LN at surgery 27
FIGO Stage
 IA 3
 IB 105
 IIA 7
Unknown 3
Histology
  Squamous Cell Carcinoma 84
 Adenocarcinoma 22
 Adenosquamous 7
 Other 5
a b
c d48
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nodes at the time of surgery. The histology was 
squamous cell carcinoma, adenocarcinoma, 
adenosquamous carcinoma and other in 84, 22, 7 
and 5 patients, respectively. FIGO stage was IA, 
IB and IIA in 3, 105, and 5 patients; it could not 
be determined deﬁ  nitively from the clinical data 
in 5 patients. The two groups did not differ sig-
niﬁ  cantly in age, with the median age 44.3 and 
45.1 years in the relapsing and non-relapsing 
patients, respectively. Of the 42 relapsing patients, 
the ﬁ  rst site(s) of failure was local in 32 and dis-
tant in 19 patients. For 9 patients, synchronous 
recurrent disease was ﬁ  rst detected locally and at 
distant sites. In the overall group, freedom from 
any recurrence (FFR) at 3, 5 and 10 years was 69, 
64 and 63%, respectively (Fig. 2). Positive lymph 
node status at surgery was associated with a sig-
nificantly worse 5-year FFR, 40 versus 72% 
(p = 0.0013, Table 2).
Though there was a weak trend for poorer FFR 
associated with higher IHC score and extent of 
CAIX staining, the difference was not signiﬁ  cant. 
However, when FFR was stratiﬁ  ed by distant 
metastases and local recurrence as the ﬁ  rst site(s) 
of failure, signiﬁ  cantly higher freedom from dis-
tant metastasis (FFDM) was associated with 
reduced CAIX staining (92 versus 74% at 5 years 
for low versus high IHC, p = 0.040) as shown in 
Figure 3. In contrast, local recurrence (Fig. 4). 
appeared to be independent of the level of CAIX 
expression (p = 0.87). Similarly, positive lymph 
node status at surgery was strongly associated with 
decreased FFDM (91 versus 55% at 5 years for 
negative versus positive lymph nodes, p   0.0001), 
while there was no signiﬁ  cant association with the 
nodal status and local recurrence. Conversely, 
there was a signiﬁ  cant association between squa-
mous histology and poorer freedom from local 
recurrence (FFLR 70% for squamous histology 
versus 90% for other histologies, p = 0.007, 
Figure 4) but no apparent association with distant 
metastases (Fig. 3).
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Figure 2. Probability of freedom from any recurrence (FFR) versus time after radical hysterectomy for all patients (a). and stratiﬁ  ed by 
positive lymph node (LN) status (b., positive versus negative), immunohistochemical (IHC) score (c.,  30 versus  30) and tumor histology 
(d., squamous cell carcinoma versus other).49
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The results of the survival analysis for the com-
bination of CAIX staining and nodal status are 
shown in Figure 5. The combination of a high 
CAIX IHC score and positive lymph nodes was 
associated with a signiﬁ  cantly poorer FFR and 
FFDM but not FFLR. For patients with elevated 
CAIX IHC score and positive nodes, FFDM at 
5 years was signiﬁ  cantly lower (50%) than that of 
patients with either positive nodes or elevated 
CAIX score alone or with neither adverse feature 
(5-year FFDM 70, 85 or 95%, respectively, 
p = 0.0004.) Likewise, the 5-year FFR’s for these 
Table 2. Freedom from recurrence (FFR), freedom from local recurrence as the ﬁ  rst site of failure (FFLR) and 
freedom from distant metastases as the ﬁ  rst site of failure (FFDM) as a function of FIGO stage, immunohisto-
chemical score (IHC), pathologic nodal status at surgery and histology on univariate analysis.
Grouping Variable 5-yr Overall FFR 5-yr FFLR 5-yr FFDM
All Eligible Patients 65%
FIGO Stage:
  IA vs IB vs IIA
100% vs 67% vs 13% 
(p = 0.019)
IHC:
   30 vs  30
71% vs 62%
(p = 0.45)
73% vs 74%
(p = 0.87)
92% vs 76%
(p = 0.040)
Lymph Nodes:
  Positive vs Negative
40% vs 73%
(p = 0.0013)
61% vs 76%
(p = 0.18)
55% vs 90%
(p   0.0001)
Histology:
  Squamous vs Other
62% vs 76%
(p = 0.076)
67% vs 90%
(p = 0.0070)
83% vs 79%
(p = 0.70)
Age:
   45 vs  45 years old
64% vs 68%
(p = 0.98)
69% vs 79%
(p = 0.50)
81% vs 83%
(p = 0.81) 
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Figure 3. Probability of freedom from distant metastases (FFDM) as ﬁ  rst site of recurrence versus time after radical hysterectomy for all 
patients (a). and stratiﬁ  ed by lymph node (LN) status (b., positive versus negative), immunohistochemical (IHC) score (c.,  30 versus  30) 
and tumor histology (d., squamous cell carcinoma versus other).50
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combination of features were 35, 50, 72 and 76%, 
respectively (p = 0.0021.) Thus, the ﬁ  nding of 
elevated CAIX expression is associated with an 
increased incidence of distant metastases, indepen-
dent of lymph node status. These results are sum-
marized in Table 3.
The results of the multivariable proportional 
hazards analysis, presented in Table 4, are con-
sistent with those of the univariate analyses. In 
the 4-variable models based on age, lymph node 
status, IHC score and histology, age never 
reached the level of signiﬁ  cance. In the 3-variable 
(lymph node status, IHC score and histology) and 
2-variable (lymph node status and histology) 
models of FFR, both lymph node status and his-
tology were signiﬁ  cantly associated with FFR. 
While the 3-variable mode of local recurrence 
showed both histology and lymph node status to 
be signiﬁ  cantly associated with FFLR, in the 
2-variable model only histology was statistically 
significant. In contrast, in both the 3- and 
2-variable models of FFDM, lymph node status 
was signiﬁ  cantly associated with distant metas-
tases as the ﬁ  rst site of failure, while IHC score 
trended toward signiﬁ  cance and histology had no 
apparent association. When cross products (IHC 
score x lymph node status, IHC score x histology, 
lymph node status x histology) were included in 
the 3-variable model for FFDM, both IHC score 
(HR = 4.99, p = 0.030) and lymph node status 
(HR = 6.76, p = 0.0015) were signiﬁ  cant.
Discussion
Prognostic signiﬁ  cance of CAIX 
overexpression
This study supports the hypothesis that hypoxia 
plays a key role in tumor metastasis, even for early-
stage cancers. In several studies, CAIX expression 
appears closely associated with tumor hypoxia 
(Jankovic et al. 2006; Loncaster et al. 2001; 
×
× ×
× × × × ×
×
× ×
×× × × ×× ×× ×× ×× × ×× ×× ×× × ×× ×× ×× × × × × ×× ×× ×× ××× × ×× ×× ××× × ×× × × × ××× ×× ×× × ×× × × × × ×× × × × × × × × ×× ×× ×× × × × × ×× ×× × × × × × ×× × × ×× ×× ×× × × ×× ×× × ×× ×× × × × × ×× × ×× × × × ××
× ×× × ×× ×××× × × ×× × × ×× × × ××× × × × ×× ×× ××
×
×××
×××× × × × × × × × ×× ×× × ×× ××××× ×× ×× ×× ×× × ××× ×× × × × × × × × ×× × × × × ×× × × ×× × × ×× × × × × × ×× ×× × × × × × × × × × × × × × × ×× × × × × × × × × × × × ×× × ×
×
×× × × ×
××× × × × × × × × × × ××× × × × × × × × × × × × × × × × × × × × × × × ×× × × × × × × × × × × × × × × ×× × × ×× × ×××××× ×× ×× ××× ×× × × × ×× ×
×
×× ×
× × × ×
×× × × ×× × ×× × × × ×× × × × × × × × × ×× × × × × × × ×× ××××× ××××× × × × × × × × ×× × ×× × × × ×
×
×× ×××× × ×
× Censored
Censored Censored Other Squamous IHC<30 IHC>30
1
0.8
0.6
0.4
0.2
0
0
1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
0
5 10 15
0 5 10 15 0 5 10 15
0 5 10 15
Time to Failure or Last Follow-up (years)
Time to Failure or Last Follow-up (years)
Time to Failure or Last Follow-up (years)
Time to Failure or Last Follow-up (years)
a. All Local Recurrences
F
r
e
e
d
o
m
 
f
r
o
m
 
L
o
c
a
l
 
R
e
c
u
r
r
e
n
c
e
F
r
e
e
d
o
m
 
f
r
o
m
 
L
o
c
a
l
 
R
e
c
u
r
r
e
n
c
e
F
r
e
e
d
o
m
 
f
r
o
m
 
L
o
c
a
l
 
R
e
c
u
r
r
e
n
c
e
F
r
e
e
d
o
m
 
f
r
o
m
 
L
o
c
a
l
 
R
e
c
u
r
r
e
n
c
e
P = .18
P = .0070 P = .87
b. Stratified  by Lymph Node Status 
d. Stratified  by Histology c. Stratified  by IHC 
Censored Positive Negative
Figure 4. Probability of freedom from local recurrence (FFLR) as ﬁ  rst site of recurrence versus time after radical hysterectomy for all patients 
(a). and stratiﬁ  ed by lymph node (LN) status (b., positive versus negative), immunohistochemical (IHC) score (c.,  30 versus  30) and 
tumor histology (d., squamous cell carcinoma versus other).51
CAIX expression in early-stage cervical cancer
Biomarker Insights 2008:3 
Airley et al. 2003), while in others the relationship 
between CAIX expression and hypoxia is unclear 
(Hedley et al. 2003; Mayer et al. 2005). Likewise, 
the prognostic signiﬁ  cance of CAIX is controver-
sial. While some studies have revealed signiﬁ  cant 
associations between CAIX and adverse outcome 
(Kim et al. 2005; Koukourakis et al. 2001 and 
2006; Giatromanolaki et al. 2001; Swinson et al. 
2003; Kim et al. 2006), others have shown no 
significant association (Kaanders et al. 2002; 
Hedley et al. 2003).
Our results for CAIX overexpression in early 
stage cervix cancer are consistent with those of 
Loncaster et al. (2001) who found a signiﬁ  cantly 
worse metastasis-free and disease-speciﬁ  c survival 
but no difference in local control when CAIX was 
overexpressed. That study was based on a retro-
spective series of 130 locally advanced patients 
× ×
× × ×
× ××× ×
×
× ×
× × × × × × × ××× × ×××× × × × ×× × × × × × × × ×
×
×× ×
× × × × × × × × × × × × ×× × × × × × × × × × × × × × × × × × × × × × ×× × × × × ×× × × × × × ×× × × × × × × × × × × × × × × × × × ×× × × × ×× × × × × × × ×× ××× × ×× × × ×
× × ×× ×× ×× ××
Time to Failure or Last Follow-up (years)
0 5 10 15
1
0.8
0.6
0.4
0.2
0
F
r
e
e
d
o
m
 
f
r
o
m
 
D
i
s
t
a
n
t
 
M
e
t
a
s
t
a
s
e
s
P = .0004
Censored
IHC<30, Positive Nodes
IHC<30, Negative Nodes
IHC>30, Negative Nodes
IHC>30, Positive Nodes
Figure 5. Probability of freedom from distant metastases (FFDM) as ﬁ  rst site of recurrence versus time after radical hysterectomy stratiﬁ  ed 
by negative lymph nodes (LN) and immunohistochemical score (IHC)  30 (n = 37), negative LN and IHC  30 (n = 54), positive LN and IHC 
 30 (n = 8) and positive LN and IHC  30 (n = 19.)
Table 3. Freedom from recurrence (FFR), freedom from local recurrence as the ﬁ  rst site of failure (FFLR) and 
freedom from distant metastases as the ﬁ  rst site of failure (FFDM) as a function of the combination of immuno-
histochemical score (IHC) and pathologic lymph node status at surgery.
Grouping Variable n 5-yr FFR 5-yr FFLR 5-yr FFDM
IHC  30, Negative 
Lymph Nodes
37 76% 71% 95%
IHC  30, Negative 
Lymph Nodes
54 72% 77% 85%
IHC  30, Positive 
Lymph Nodes
8 50% 57% 70%
IHC  30, Positive 
Lymph Nodes
19 35% 61% 50%
P 0.0021 0.55 0.000452
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treated with deﬁ  nitive radiation therapy. Likewise, 
Kim et al. (2006) found that CAIX overexpression 
was the most statistically significant factor 
associated with distant metastases-free survival in 
a group of 59 primarily locally advanced cervical 
cancer patients treated with radiotherapy. However, 
their multivariable analysis did not include lymph 
node status as a one of the factors. In contrast, a 
series of 110 patients from Hedley et al. (2003) did 
not ﬁ  nd signiﬁ  cant associations between CAIX 
expression and either tumor pO2 levels or patient 
outcome in locally advanced carcinomas of the 
cervix treated with radiotherapy or radiochemo-
therapy. While this study looks at a patient popula-
tion with an earlier stage of disease treated by a 
different modality (surgery, rather than radio-
therapy), there appears to be a signiﬁ  cant relation-
ship between CAIX expression and increased 
metastatic potential. Thus, these results suggest 
that a hypoxic microenvironment is directly asso-
ciated with a more aggressive cervical cancer 
phenotype present early in development of a tumor 
and that the poorer outcome is not merely due to 
decreased radioresistance of the more hypoxic 
tumors.
The cause-and-effect relationship between 
tumor hypoxia, HIF-1α, CAIX and clinical out-
come remains unsettled (Moon et al. 2007). For 
example, in a study of locally advanced cervical 
cancer, Hutchison et al. (2004) found weak, but 
statistically signiﬁ  cant, correlations of HIF-1α 
expression with lower tumor pO2 and CAIX but 
no correlation of HIF-1α with clinical outcome. 
Elucidation of these relationships is complicated 
by the inherent macroscopic and microscopic het-
erogeneity of partially hypoxic tissues. Cline et al. 
(1997) have shown that sampling errors related to 
this heterogeneity can produce signiﬁ  cant varia-
tions in the estimated fraction of hypoxic tissue. 
In addition, determining the extent and intensity 
of staining for an endogenous hypoxic marker is 
technique dependent. It is not clear how much of 
the apparent discrepancies in clinical outcome 
versus the extent/intensity of CAIX staining 
between studies is due to differences in staining 
methodology.
Other series have demonstrated associations 
between hypoxia and nodal status using radiologic 
assessment. Fyles et al. (2002) demonstrated 
hypoxia as an independent predictor of outcome 
only in patients with node negative cervix cancer, 
again using radiologic nodal assessment in the set-
ting of deﬁ  nitive radiation therapy. The well-estab-
lished association between positive lymph node 
Table 4. Proportional hazard ratios (HR), 95% conﬁ  dence intervals (CI) and chi-square P obtained by ﬁ  tting 
survival data to 2- and 3-variable Cox proportional hazard model. The models yield qualitatively similar results 
when age as a continuous variable or second-order terms (cross-products of the independent variables) are 
added to the models, though none of these variables approach statistical signiﬁ  cance. However, when cross-
products are included in the 3-variable model ﬁ  t to ﬁ  rst failure as distant metastases, both IHC (HR = 4.99, CI 
1.14-61.4, P = 0.030) and lymph node status (HR = 6.76, CI 2.12-25.2, P = .0015) are signiﬁ  cant.
3-Variable Model Proportional Hazard Ratio (Conﬁ  dence Interval)
p
Any Failure Local Failure Distant Metastases
IHC:
   30 vs  30
1.07 (0.57–2.12)
p = 0.83
0.81 (0.40–1.70)
p = 0.58
2.78 (0.91–12.1)
p = 0.075
Lymph Nodes:
  Positive vs Negative
3.24 (1.66–6.16)
p = 0.0008
2.34 (1.00–5.03)
p = 0.049
4.74 (1.83–12.4)
p = 0.0016
Histology:
  Squamous vs Other
2.56 (1.22–6.05)
p = 0.012
5.37 (1.87–22.7)
p = 0.0008
1.13 (0.44–3.16)
p = 0.79
2-Variable Model Proportional Hazard Ratio (Conﬁ  dence Interval)
p
Any Failure Local Failure Distant Metastases
IHC:
   30 vs  30
2.82 (0.57–2.12)
p = 0.069
Lymph Node Status:
  Positive vs Negative
3.28 (1.69–6.18)
p = 0.0007
2.27 (0.98–4.83)
p = 0.056
4.58 (1.83–11.64)
p = 0.0015
Histology:
  Squamous vs Other
2.57 (1.23–6.08)
p = 0.0108
5.27 (1.83–22.2)
p = 0.000953
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status and adverse outcome (Sundfor et al. 1998; 
Ho et al. 2004) was also conﬁ  rmed in our study.
Measurement of tumor oxygenation
Typically, tumor oxygenation is directly mea-
sured using microelectrodes or RuO2 microprobes 
(Brown and Le, 2002). However, these tech-
niques involve an invasive procedure, which 
restricts their use to accessible tumors. Hypoxia 
marker drugs, such as nitromidazole derivatives 
(e.g., EF5 and pimonidazole), also have been 
used to detect hypoxia in tissue specimens. 
Though these methods effectively and quantita-
tively identify the extent and degree of hypoxia, 
the requirement for administration prior to biopsy 
limits their clinical use to prospective studies 
(Kaanders et al. 2002; Evans et al. 2000). Alter-
natively, it would be advantageous to assess 
tumor hypoxia using endogenous markers that 
can be detected in routine clinical biopsy speci-
mens, obviating the need for an invasive proce-
dure and pre-biopsy marker drug administration 
(Moon et al. 2007). Thus, one potentially power-
ful advantage of the CAIX technique is that it 
can be applied to parafﬁ  n-embedded tissues, 
enabling analysis of relatively large series with 
long clinical follow-up.
Clinical implications of tumor hypoxia
Tumor hypoxia is a complex entity which is a 
function of both oxygen supply and demand. On 
the supply side, deﬁ  ciencies in the nutrient supply, 
such as low vascular density and uneven vascular 
distribution may play a role. On the demand side, 
abnormalities in energy metabolism are known to 
be related to defects in regulation of respiratory 
enzymes, combined with high demand for energy 
in the setting of rapid cellular proliferation. A shift 
toward anaerobic metabolism would decrease 
oxygen consumption rates, which could lead to 
improvement in tumor oxygenation. Theoretical 
modeling of the relative contributions from perfu-
sion and consumption on tumor oxygenation came 
to the conclusion that manipulation of oxygen 
consumption is an order of magnitude more effec-
tive in changing tumor hypoxia than changing 
perfusion (Secomb et al. 1998). Thus, even a small 
decrease in respiration (i.e., oxygen consumption) 
could potentially lead to profound changes in tumor 
oxygenation.
Low oxygen tension appears to be a clinically 
relevant feature of the tumor microenvironment, 
but the optimal intervention to ameliorate the 
effects of hypoxia remains uncertain (Coleman 
et al. 2004). Possible avenues of exploration 
include strategies to correct the underlying 
pathophysiologic process which led to hypoxia, 
and, thus, to inﬂ  uence the downstream expres-
sion of angiogenic and apoptotic factors. Alter-
natively, the microenvironment could be left 
unperturbed and hypoxic cell sensitizers or 
hypoxic cytotoxic therapy, such as tirapazamine 
or banoxantrone, could be utilized to eradicate 
the hypoxic cell subpopulation (McKeown et al. 
2007).
Future directions
The role of CAIX expression as a biomarker 
predicting an increased risk of distant metastases 
needs to be validated in an independent data set. 
In addition, microarray techniques used in pro-
spective trials will eventually have the potential 
to identify genomic signatures which correlate 
with hypoxia, nodal metastasis and overall 
clinical outcomes. Emerging nuclear medicine 
PET-imaging techniques, utilizing agents such 
as F-MISO and Cu-ATSM, may enable non-
invasive assessment of hypoxia as a further cor-
relate in the initial staging (Rajendran et al. 
2005). It will be important to use these genomic 
and molecular/physiologic imaging strategies to 
validate our observation of hypoxia and distant 
metastasis in early-stage cervix cancer. This 
tactic would provide a selection criterion for 
early-stage patients who may beneﬁ  t from novel 
adjuvant systemic therapy. Applying these 
genomic and molecular/physiologic imaging 
strategies in more advanced stage patients might 
lead to a better understanding of the mechanisms 
of action for hypoxia-induced gene therapy, HIF-
targeted therapy and anti-angiogenic and anti-
vascular therapies.
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